News
BILENDI: The latest version of Bilendi Discuss fully automates market research studies from initial objective to final report using AI
BILENDI: Bilendi announces the completion of the acquisition of Netquest
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
Regulatory News:
Median Technologies (Paris:ALMDT):
Fredrik Brag, CEO of Median Technologies, will host two webcasts on February 4, 2025
“New Horizons in Fighting Lung Cancer: eyonis™ LCS
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
BILENDI: Launch of Bilendi Platform: Redefining Efficiency in Market Research
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Median Technologies: Financial Communications Schedule for the First Half of 2025
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results:
Publication
Date
2024
BILENDI: Bilendi launches a US panel as part of its panel expansion strategy
Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
BILENDI: Bilendi announces the acquisition of Netquest, leader in technologies and data for market research in Iberia and Latin America